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Abstract: Fabry disease is a x-linked lysosomal storage disease leading to early death related to renal,
cardiac, and cerebrovascular disease. Therefore, proper diagnosis and therapy of elevated blood pressure
may improve morbidity and mortality of these patients. However, the prevalence of uncontrolled hyper-
tension in Fabry disease is unknown. We examined blood pressure of patients with Fabry disease using a
large international database, the Fabry Outcome Survey (FOS). We defined uncontrolled hypertension as
a systolic blood pressure (SBP) ￿130, and/or a diastolic blood pressure (DBP) ￿ 80 mmHg (threshold for
blood pressure control in renal disease, JNC7). We used the short MDRD-GFR formula for assessment of
renal function, and we classified chronic kidney disease according to K/DOQI. Among 459 patients with
Fabry disease, 306 had blood pressure readings entered in the database. Mean SBP was 124.6 ± 16.9
mmHg and mean DBP was 73.6 ± 11.7 mmHg (mean age: 38.4 ± 15.6 years, 142 females, 164 males).
Fourty-three percent of men and and 28% of women showed uncontrolled hypertension. In 291 patients
both, blood pressure readings and GFR estimates, were available. In patients with normal GFR (>90
ml/min/1.73m2) mean SBP was 119.5 ± 15.6 mmHg and mean DBP was 69.7 ± 11.1 mmHg (n=120). In
patients with mild decreased GFR (60-89 ml/min/1.73m2) mean SBP was 126.7 ± 15.9 mmHg and mean
DBP was 75.0 ± 11.0 mmHg (n=110). In patients with moderate decreased GFR (30-59 ml/min/1.73m2)
mean SBP was 132.7 ± 20.8 mmHg and mean DBP was 79.0 ± 13.3 mmHg (n=41). In 70 patients blood
pressure readings were available before start of enzyme replacemen therapy (ERT) with agalsidase alfa
(Replagal, TKT 5S Europe, 0.2 mg/kg bodyweight fortnightly i.v.), in 87 at 12 months and in 76 at 24
months of therapy. At baseline, at 12 and at 24 months of ERT, 39%, 30% and 42%of the patients pre-
sented with uncontrolled hypertension, respectively. Our study revealed a high prevalence of uncontrolled
hypertension among patients with Fabry disease. Thus, there is need for improvement of blood pressure
control in these patients. Am J Hypertens (2004) 17, 206A-206A; doi: 10.1016/j.amjhyper.2004.03.549
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stroke, heart failure renal failure and peripheral vascular disease from
hypertension. At present, coronary heart disease is relatively uncommon,
probably because Blacks in SSA have lower cholesterol levels and higher
high-density lipoprotein cholesterol levels compared to the Caucasian
population group in the Western world, the Asian and Caucasian popu-
lation in SSA and in African Americans. Although there are good studies
on the response and tolerability of antihypertensive drugs in SSA, there
are no long-term morbidity and mortality data available.
Recommendations of the International Forum for Hypertension Con-
trol and Prevention in Africa (IFHA) have been documented. It should be
emphasised that, while it is important to consider the science of medicine
for the treatment of hypertension, particular consideration should be
given to cost-effectiveness and affordability because many countries in
SSA have severe resource restraints. In some of them, the health budget
per capita does not exceed US$10 per year and this is insufficient to
address the needs posed by the double burden of NCD and infectious
diseases, including AIDS.
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The Japan lipid intervention trial (J-LIT) was primarily conducted to
clarify the relationship between serum lipid levels and incidence of
cardiovascular event (CE) in Japanese patients with hypercholesterol-
emia (Circ J 2002; 66: 1087). Hypertension is one of the major risk
factors for coronary heart disease (CHD) or stroke. We analyzed the
results of primary prevention cohort in the J-LIT study, focusing on the
relationship between blood pressure (BP) and the risk of CE, stroke or
total CE in patients with hypercholesterolemia.
All patients (n40,229) were treated with open-labeled simvastatin
mainly at a dose of 5 mg/day for 6 years. According to the control level
of serum total cholesterol (TC), patients were divided into two groups,
less-controlled (L) (TC 220 mg/dL, n5,548(male), 13,421(female))
and well-controlled (W) (TC220 mg/dL, n7,039(male), 14,213(fe-
male)) groups. We examined the effect of BP during the lipid-lowering
therapy on the risk of CE and stroke comparing L with W group. The
primary endpoint of the sub-analysis was stroke or CE such as acute
myocardial infarction or sudden cardiac death, or total CE (CEstroke).
The average age was 53.99.1 in male and 59.46.5 years old in
female. The incidences of CE and stroke under lipid lowering therapy
were 1.47 and 3.05 in male and 0.59 and 2.14 per 1,000 patients-years in
female, respectively. The adjusted relative risk of total CE in the L group
was increased at lower level of BP compared to the W group in both
genders. The levels of systolic BP for total CE risk in the L group were
130 mmHg in both genders. However those levels in the W group were
140 mmHg in male and 150 mmHg in female. The levels of diastolic
BP for total CE risk in the L group were 80 mmHg in both genders.
Those levels in the W group were 90 mmHg in male and 80 mmHg
in female.
The risk of CE or stroke was increased with increase of BP in patients
with hypercholesterolemia regardless the controlled level of TC. For
patients with hypercholesterolemia and hypertension, we concluded that
BP should be controlled strictly for the prevention of CE or stroke in
addition to lowering serum TC.
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Fabry disease is a x-linked lysosomal storage disease leading to early
death related to renal, cardiac, and cerebrovascular disease. Therefore,
proper diagnosis and therapy of elevated blood pressure may improve
morbidity and mortality of these patients. However, the prevalence of
uncontrolled hypertension in Fabry disease is unknown.
We examined blood pressure of patients with Fabry disease using a
large international database, the Fabry Outcome Survey (FOS). We
defined uncontrolled hypertension as a systolic blood pressure (SBP)
130, and/or a diastolic blood pressure (DBP)  80 mmHg (threshold
for blood pressure control in renal disease, JNC7). We used the short
MDRD-GFR formula for assessment of renal function, and we classified
chronic kidney disease according to K/DOQI.
Among 459 patients with Fabry disease, 306 had blood pressure
readings entered in the database. Mean SBP was 124.6  16.9 mmHg
and mean DBP was 73.6  11.7 mmHg (mean age: 38.4  15.6 years,
142 females, 164 males). Fourty-three percent of men and and 28% of
women showed uncontrolled hypertension. In 291 patients both, blood
pressure readings and GFR estimates, were available. In patients with
normal GFR (90 ml/min/1.73m2) mean SBP was 119.5  15.6 mmHg
and mean DBP was 69.7  11.1 mmHg (n120). In patients with mild
decreased GFR (60-89 ml/min/1.73m2) mean SBP was 126.7  15.9
mmHg and mean DBP was 75.0 11.0 mmHg (n110). In patients with
moderate decreased GFR (30-59 ml/min/1.73m2) mean SBP was 132.7
20.8 mmHg and mean DBP was 79.0  13.3 mmHg (n41). In 70
patients blood pressure readings were available before start of enzyme
replacemen therapy (ERT) with agalsidase alfa (Replagal, TKT 5S Eu-
rope, 0.2 mg/kg bodyweight fortnightly i.v.), in 87 at 12 months and in
76 at 24 months of therapy. At baseline, at 12 and at 24 months of ERT,
39%, 30% and 42%of the patients presented with uncontrolled hyper-
tension, respectively.
Our study revealed a high prevalence of uncontrolled hypertension
among patients with Fabry disease. Thus, there is need for improvement
of blood pressure control in these patients.
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